KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Medical - Instruments & Supplies
Market Cap$1.26B
5Y Perf.-13.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KMTS vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.+193.1%
KMTS vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KMTS | DBVT |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Biotechnology |
| Market Cap | $1.26B | $1712.35T |
| Revenue (TTM) | $84M | $0.00 |
| Net Income (TTM) | $-145M | $-168M |
| Gross Margin | 48.8% | — |
| Operating Margin | -171.5% | — |
| Total Debt | $44M | $22M |
| Cash & Equiv. | $238M | $194M |
KMTS vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KMTS
DBVT
| Stock | Mar 25 | May 26 | Return |
|---|---|---|---|
| KESTRA MEDICAL TECH… (KMTS) | 100 | 86.4 | -13.6% |
| DBV Technologies S.… (DBVT) | 100 | 293.1 | +193.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KMTS vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KMTS and DBVT are tied at the top with 3 categories each — the right choice depends on your priorities. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
The Income Pick
KMTS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 5 yrs, beta 1.87, yield 0.2%
- Rev growth 115.1%, EPS growth -151.5%
- -1.5% 10Y total return vs DBVT's -87.0%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Defensive Pick
DBVT is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
- 0.3% margin vs KMTS's -173.0%
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KMTS | 115.1% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs KMTS's -173.0% |
| Stability / Safety | DBVT | Beta 1.26 vs KMTS's 1.87, lower leverage |
| Dividends | KMTS | 0.2% yield; 5-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs KMTS's -1.5% |
| Efficiency (ROA) | KMTS | -48.8% ROA vs DBVT's -89.0% |
KMTS vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGKMTS
KMTSKESTRA MEDICAL TECHNO…
2leads
DBVTDBV Technologies S.A.
3leads
6 Total Categories
CATEGORYLEADERvs KMTSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KMTS6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
KMTS1/1
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KMTS and DBVT operate at a comparable scale, with $84M and $0 in trailing revenue.
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $84M | $0 |
| EBITDAEarnings before interest/tax | -$142M | -$112M |
| Net IncomeAfter-tax profit | -$145M | -$168M |
| Free Cash FlowCash after capex | -$120M | -$151M |
| Gross MarginGross profit ÷ Revenue | +48.8% | — |
| Operating MarginEBIT ÷ Revenue | -171.5% | — |
| Net MarginNet income ÷ Revenue | -173.0% | — |
| FCF MarginFCF ÷ Revenue | -143.3% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +62.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -22.0% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KMTS and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $1.3B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -4.19x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 20.99x | — |
| Price / BookPrice ÷ Book value/share | 5.19x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — KMTS and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
KMTS leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
KMTS delivers a -68.8% return on equity — every $100 of shareholder capital generates $-69 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to KMTS's 0.22x. On the Piotroski fundamental quality scale (0–9), KMTS scores 6/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -68.8% | -130.2% |
| ROA (TTM)Return on assets | -48.8% | -89.0% |
| ROICReturn on invested capital | -6.6% | — |
| ROCEReturn on capital employed | -78.6% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.22x | 0.13x |
| Net DebtTotal debt minus cash | -$193M | -$172M |
| Cash & Equiv.Liquid assets | $238M | $194M |
| Total DebtShort + long-term debt | $44M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -13.93x | -189.82x |
KMTS leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KMTS five years ago would be worth $9,853 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs KMTS's -1.5%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs KMTS's -0.5% — a key indicator of consistent wealth creation.
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -11.8% | +4.9% |
| 1-Year ReturnPast 12 months | -1.5% | +110.4% |
| 3-Year ReturnCumulative with dividends | -1.5% | +19.7% |
| 5-Year ReturnCumulative with dividends | -1.5% | -69.1% |
| 10-Year ReturnCumulative with dividends | -1.5% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -0.5% | +6.2% |
DBVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than KMTS's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs KMTS's 71.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.87x | 1.26x |
| 52-Week HighHighest price in past year | $30.00 | $26.18 |
| 52-Week LowLowest price in past year | $13.25 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +71.7% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 48.1 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 357K | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
KMTS leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates KMTS as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 30.1% for KMTS (target: $28). KMTS is the only dividend payer here at 0.16% yield — a key consideration for income-focused portfolios.
| Metric | KMTSKESTRA MEDICAL TE… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $28.00 | $46.33 |
| # AnalystsCovering analysts | 4 | 15 |
| Dividend YieldAnnual dividend ÷ price | +0.2% | — |
| Dividend StreakConsecutive years of raises | 5 | 0 |
| Dividend / ShareAnnual DPS | $0.03 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
KMTS leads this category, winning 1 of 1 comparable metric.
Key Takeaway
DBVT leads in 3 of 6 categories (Income & Cash Flow, Total Returns). KMTS leads in 2 (Profitability & Efficiency, Analyst Outlook). 1 tied.
Best OverallDBV Technologies S.A. (DBVT)Leads 3 of 6 categories
Loading custom metrics...
KMTS vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is KMTS or DBVT a better buy right now?
Analysts rate KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KMTS or DBVT?
Over the past 5 years, KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) delivered a total return of -1. 5%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: KMTS returned -1. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KMTS or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus KESTRA MEDICAL TECHNOLOGIES, LTD. 's 1. 87β — meaning KMTS is approximately 49% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 22% for KESTRA MEDICAL TECHNOLOGIES, LTD. — giving it more financial flexibility in a downturn.
04Which is growing faster — KMTS or DBVT?
On earnings-per-share growth, the picture is similar: KESTRA MEDICAL TECHNOLOGIES, LTD.
grew EPS -151. 5% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KMTS or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -190. 3% for KESTRA MEDICAL TECHNOLOGIES, LTD. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -177. 8% for KMTS. At the gross margin level — before operating expenses — KMTS leads at 40. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — KMTS or DBVT?
In this comparison, KMTS (0.
2% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.
07Is KMTS or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, KMTS: -1. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KMTS and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KMTS is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.